Cytogenix (fka CYGX)

[neo43]

One reason Isis' SP is higher . . .

is because it's further along in developing marketable drugs:

Isis’ antisense product pipeline is the company’s most valuable asset. The company's goal is to advance multiple antisense drugs in parallel, providing it with many opportunities for clinical success. Isis has successfully commercialized the world’s first antisense drug, Vitravene® and has created a robust product pipeline with the following characteristics:

- 11 products in development for short and long term treatment of multiple chronic conditions

- Two Phase III and several Phase II programs

- Multiple products based on first-generation chemistry to treat illnesses such as cancer, severe inflammatory diseases and hepatitis C

- Multiple products based on second-generation chemistry to treat diabetes, rheumatoid arthritis, psoriasis, multiple sclerosis and cardiovascular disease.

- Multiple formulations in development: intravenous, subcutaneous, topical cream, enema, intravitreal, inhalation and oral.

http://www.isispharm.com/antisense_pipeline.html